Suven Life Sciences Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Suven Life Sciences Ltd.
Aceto has received approval to divest its Rising Pharmaceuticals unit to Shore Suven Pharma for $15m as part of bankruptcy proceedings.
Lundbeck says it remains committed to developing new Alzheimer's disease drugs with a variety of different mechanisms, after the unsurprising failure of 5HT6 antagonist idalopirdine in two more Phase III studies.
Presentation of data at Alzheimer’s Association International Conference highlights failure of Pfizer’s 5HT6 antagonist PF-05212377, while still leaving room to hope for others in class like Lundbeck’s idalopirdine and Axovant’s RVT-101
Alzheimer's disease (AD) drug developer Axovant Sciences, which earlier this year raised a record-breaking sum of cash, has launched a large Phase III study for its 5-HT6 receptor antagonist, RVT-101– a move it hopes will set the company up to seek the first approval for any new AD product in over a decade.
- In Vitro Diagnostics
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Drug Delivery
- Drug Discovery Tools
Drug Discovery Tools
- Molecular Diversity
- Other Names / Subsidiaries
- SUVEN LIFE Sciences Limited
- Suven Neurosciences Inc
- Suven Inc
- SUVEN PHARMACEUTICALS LIMITED